Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Management at Greatbatch, Inc. (GB - Analyst Report) announced a strategic initiative to realign its business to achieve 5% organic growth. The company aims to combine its two separate reportable segments viz. Greatbatch Medical and Electrochem Solutions into a single sales & marketing and operating group.  

The company has appointed 4 new senior executives following the realignment decision. It expects to incur restructuring charges in the range of $4.2 to $5.0 million, including employee severance and termination benefits.

Following its completion, the realignment plan is expected to generate annual savings of $7.0 to $7.7 million. Moreover, evaluating the short-term benefit from the realignment plan, Greatbatch has raised its adjusted earnings per share guidance range to $2.00– $2.05 from the previous range of $1.90–$2.00 per share.

With the success of its integration and consolidation efforts, Greatbatch is now shifting its focus to become a producer of complete medical devices for Original Equipment Manufacturer (OEM) customers from being a supplier of batteries, capacitors, and components used in implantable medical devices (IMDs).

Moreover, Greatbatch boasts a vast intellectual property (IP) portfolio of more than 1,000 patents. The IP along with better sales and marketing initiatives will allow the company to gain market share in the multi-billion dollar worth cardiac and neuromodulation, portable medical, vascular and orthopedics markets.

Our Take

We believe that the realignment plan will help management to emphasize on investing in its core business as well as develop innovative products by combining the resources of the integrated unit. We are also encouraged by Greatbatch’s effort to transform into a medical devices company. Almost 80% of its revenues are derived from medical devices companies. Its top customers include leading players such as Medtronic (MDT - Analyst Report) and St. Jude Medical (STJ - Analyst Report).

Greatbatch, Inc. currently retains a Zacks Rank #3 (Hold). A soft CRM market and pricing pressure remain headwinds for the company. While we remain on the sidelines for Greatbatch, semi-discretes company Vishay Intertechnology Inc. (VSH - Snapshot Report) with a Zacks Rank #2 (Buy) warrants a look.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%